FDA Approves TECENTRIQ — SUPPL Submission by GENENTECH INC, Not disclosed in the FDA record.

Key facts

What was approved

FDA's record shows GENENTECH INC as the sponsor of TECENTRIQ, with the generic name recorded as unspecified and dosage form INJECTABLE. A Biologics License Application (BLA) is the FDA pathway used to approve biologic products (such as vaccines, blood products, and cell/gene therapies), requiring evidence of safety, purity, and potency along with manufacturing-process validation specific to biologic manufacturing. This specific application is submission type SUPPL (submission number 65) under application number BLA761034, with a submission status date of 20261008. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Regulatory context

This application was reviewed under FDA's SUPPL submission pathway. A Biologics License Application (BLA) is the FDA pathway used to approve biologic products (such as vaccines, blood products, and cell/gene therapies), requiring evidence of safety, purity, and potency along with manufacturing-process validation specific to biologic manufacturing. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

GENENTECH INC’s FDA history

Argus HQ has recorded 2 total FDA actions tied to GENENTECH INC: 0 warning letters, 0 recalls, 2 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

What does the submission type mean?

A Biologics License Application (BLA) is the FDA pathway used to approve biologic products (such as vaccines, blood products, and cell/gene therapies), requiring evidence of safety, purity, and potency along with manufacturing-process validation specific to biologic manufacturing.

Is this product available now?

FDA's record lists a submission status date of 20261008. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does GENENTECH INC have other FDA approval records?

Yes. Argus HQ has recorded 2 total FDA actions tied to GENENTECH INC, including 2 approval records.

What is the FDA application number for this submission?

FDA application number BLA761034, submission 65.

Related enforcement actions

• Approval: GENENTECH INC — BLA approval: TECENTRIQ HYBREZA (unspecified) →
• Approval (recent): AUROBINDO PHARMA LTD — ANDA approval: SOLRIAMFETOL (unspecified) →
• Approval (recent): RUBICON RESEARCH — ANDA approval: HYDROCHLOROTHIAZIDE (unspecified) →
• Approval (recent): HIKMA — ANDA approval: FIDAXOMICIN (unspecified) →
• Approval (recent): CREEKWOOD PHARMS — ANDA approval: MIRABEGRON (unspecified) →
• Approval (recent): ASTRAZENECA AB — NDA approval: BREZTRI AEROSPHERE (unspecified) →
• Approval (recent): TEVA NEUROSCIENCE INC — NDA approval: WELTRUZA (unspecified) →
• Approval (recent): ANNORA PHARMA PRIVATE LIMITED — ANDA approval: PITOLISANT (unspecified) →